Intrinsiqs

Is Halozyme Therapeutics, Inc. overvalued?

Halozyme Therapeutics, Inc. (HALO) looks undervalued — trading about 18% below its fair value.

Undervalued
Current price $100.06 Fair value $117.77
Price
$100.06
Fair value
$117.77
Current P/E
21.7
Normal P/E
25.5
Market cap
$11.87B
Dividend yield
0.0%
Return on equity
180.6%
Sector
Healthcare

See the full interactive analysis →

Fair value compares HALO's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.

Related stocks

LLY Eli Lilly and CompanyJNJ Johnson & JohnsonABBV AbbVie Inc.RHHBY Roche Holding AGUNH UnitedHealth Group IncorporatedMRK Merck & Co., Inc.